|
AU2003243151A1
(en)
*
|
2002-08-16 |
2004-03-03 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
|
US7480593B2
(en)
*
|
2005-08-03 |
2009-01-20 |
Suresh Gopalan |
Methods and systems for high confidence utilization of datasets
|
|
ES2625259T3
(es)
*
|
2006-08-29 |
2017-07-19 |
Oxford Biotherapeutics Ltd |
Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
|
|
AR072999A1
(es)
*
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
JP2012513194A
(ja)
*
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α５β１に向けられた標的結合剤およびその使用
|
|
WO2010087743A2
(en)
|
2008-12-30 |
2010-08-05 |
Cellartis Ab |
The use of a protein in stem cell and cancer applications
|
|
PT2403878T
(pt)
|
2009-03-05 |
2017-09-01 |
Squibb & Sons Llc |
Anticorpos completamente humanos específicos a cadm1
|
|
WO2011124635A1
(en)
|
2010-04-07 |
2011-10-13 |
Humalys |
Binding molecules against chikungunya virus and uses thereof
|
|
EP2374816B1
(en)
*
|
2010-04-07 |
2016-09-28 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
|
NZ604007A
(en)
*
|
2010-05-27 |
2015-03-27 |
Genmab As |
Monoclonal antibodies against her2 epitope
|
|
CA3051311A1
(en)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Monoclonal antibodies against her2
|
|
KR102024922B1
(ko)
|
2010-07-16 |
2019-09-25 |
아디맵 엘엘씨 |
항체 라이브러리
|
|
SG189212A1
(en)
*
|
2010-09-03 |
2013-05-31 |
Stem Centrx Inc |
Identification and enrichment of cell subpopulations
|
|
WO2012031273A2
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
|
US9778264B2
(en)
|
2010-09-03 |
2017-10-03 |
Abbvie Stemcentrx Llc |
Identification and enrichment of cell subpopulations
|
|
AU2015234335B2
(en)
*
|
2010-09-29 |
2017-09-28 |
Agensys, Inc. |
Antibody drug conjugates (ADC) that bind to 191P4D12 proteins
|
|
EP2621526B1
(en)
|
2010-09-29 |
2018-06-06 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to 191p4d12 proteins
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
CN103534272B
(zh)
|
2011-05-09 |
2016-05-11 |
株式会社英仙蛋白质科学 |
能够特异性识别转铁蛋白受体的抗体
|
|
EP2793945B1
(en)
*
|
2011-12-05 |
2018-08-15 |
Trellis Bioscience, LLC |
Antibodies useful in passive influenza immunization
|
|
AU2013215254B2
(en)
*
|
2012-01-31 |
2017-08-31 |
Regeneron Pharmaceuticals, Inc. |
Anti-ASIC1 antibodies and uses thereof
|
|
JP5939855B2
(ja)
*
|
2012-03-23 |
2016-06-22 |
国立大学法人 宮崎大学 |
トランスフェリン受容体抗体
|
|
JP6429771B2
(ja)
|
2012-06-21 |
2018-11-28 |
ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
ｃ−Ｍｅｔに結合する抗原結合タンパク質
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
CA2893794C
(en)
|
2012-11-08 |
2021-11-09 |
University Of Miyazaki |
Antibody capable of specifically recognizing transferrin receptor
|
|
ES2742413T3
(es)
*
|
2012-11-21 |
2020-02-14 |
Km Biologics Co Ltd |
Nuevo anticuerpo humano contra IL-18
|
|
JP6595448B2
(ja)
|
2013-03-14 |
2019-10-23 |
コントラフェクト コーポレイション |
治療効率の増強のために鼻腔内送達する中和抗体に基づく組成物および方法
|
|
WO2015053871A2
(en)
*
|
2013-08-26 |
2015-04-16 |
MabVax Therapeutics, Inc. |
NUCLEIC ACIDS ENCODING HUMAN ANTIBODIES TO SIALYL-LEWISa
|
|
EP3042956A4
(en)
|
2013-09-05 |
2017-03-15 |
University of Miyazaki |
Antibody which specifically reacts with human integrin a6b4
|
|
AU2014323523B2
(en)
|
2013-09-20 |
2020-02-20 |
Bristol-Myers Squibb Company |
Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
|
|
CA2935423C
(en)
|
2014-01-24 |
2023-11-07 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to pd-1 and uses thereof
|
|
US10639370B2
(en)
|
2014-02-04 |
2020-05-05 |
Contrafect Corporation |
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
|
|
KR102344390B1
(ko)
|
2014-02-04 |
2021-12-28 |
콘트라펙트 코포레이션 |
수동 인플루엔자 면역화에 유용한 항체, 및 이의 사용을 위한 조성물, 조합 및 방법
|
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
US20170173005A1
(en)
|
2014-03-27 |
2017-06-22 |
Research Foundation Of The City University Of New York |
Method for detecting or treating triple negative breast cancer
|
|
US9975960B2
(en)
*
|
2014-05-09 |
2018-05-22 |
Samsung Electronics Co., Ltd. |
Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
|
|
KR102401595B1
(ko)
*
|
2014-05-09 |
2022-05-24 |
삼성전자주식회사 |
항 HER2 scFv 단편 및 이를 포함하는 항 c-Met/항 HER2 이중 특이 항체
|
|
JP7037359B2
(ja)
|
2014-10-10 |
2022-03-16 |
イナート・ファルマ・ソシエテ・アノニム |
Ｃｄ７３遮断
|
|
KR102781223B1
(ko)
|
2014-11-10 |
2025-03-12 |
메디뮨 리미티드 |
Cd73에 특이적인 결합 분자 및 이의 용도
|
|
PL3221346T3
(pl)
|
2014-11-21 |
2021-03-08 |
Bristol-Myers Squibb Company |
Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
|
|
TWI711630B
(zh)
|
2014-11-21 |
2020-12-01 |
美商必治妥美雅史谷比公司 |
抗ｃｄ７３抗體及其用途
|
|
RU2698205C2
(ru)
|
2014-12-18 |
2019-08-23 |
Ф. Хоффманн-Ля Рош Аг |
Способ определения антител, вызывающих комплемент-зависимую цитотоксичность
|
|
EP3259288A1
(en)
*
|
2015-02-20 |
2017-12-27 |
Innate Pharma |
Cd73 blockade
|
|
US10233244B2
(en)
|
2015-05-04 |
2019-03-19 |
Cytomx Therapeutics, Inc. |
Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof
|
|
SG10202110908WA
(en)
|
2015-05-04 |
2021-11-29 |
Cytomx Therapeutics Inc |
Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
|
|
JP7420334B2
(ja)
*
|
2015-06-25 |
2024-01-23 |
株式会社カネカ |
液体注入方法
|
|
CN108351287B
(zh)
*
|
2015-07-15 |
2019-08-09 |
贝克顿迪金森公司 |
用于调整细胞仪测量的系统和方法
|
|
ES2878188T3
(es)
|
2015-07-29 |
2021-11-18 |
Novartis Ag |
Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
|
|
WO2017064043A1
(en)
|
2015-10-12 |
2017-04-20 |
Innate Pharma |
Cd73 blocking agents
|
|
WO2018013611A1
(en)
*
|
2016-07-11 |
2018-01-18 |
Corvus Pharmaceuticals, Inc. |
Anti-cd73 antibodies
|
|
EP3484923A1
(en)
|
2016-07-15 |
2019-05-22 |
Takeda Pharmaceutical Company Limited |
Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
|
|
AU2017307610B2
(en)
*
|
2016-08-04 |
2023-10-05 |
Memorial Sloan-Kettering Cancer Center |
Cancer antigen targets and uses thereof
|
|
US10617720B2
(en)
*
|
2016-10-20 |
2020-04-14 |
Miltenyi Biotech, GmbH |
Chimeric antigen receptor specific for tumor cells
|
|
IL324632A
(en)
|
2016-12-01 |
2026-01-01 |
Regeneron Pharma |
Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging
|
|
MX392340B
(es)
*
|
2016-12-13 |
2025-03-21 |
Astellas Pharma Inc |
Anticuerpo anti cd73 humana.
|
|
UA126571C2
(uk)
|
2017-01-24 |
2022-11-02 |
Ай-Маб Байофарма Юес Лімітед |
Антитіло до cd73 та його застосування
|
|
CA3060984A1
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Treatment of lag-3 positive tumors
|
|
KR102721137B1
(ko)
|
2017-05-30 |
2024-10-25 |
브리스톨-마이어스 스큅 컴퍼니 |
항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
|
|
WO2018237173A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
|
|
SG11202000105QA
(en)
|
2017-07-14 |
2020-02-27 |
Cytomx Therapeutics Inc |
Anti-cd166 antibodies and uses thereof
|
|
US12371506B2
(en)
|
2018-01-12 |
2025-07-29 |
Takeda Pharmaceutical Company Limited |
Subcutaneous administration of anti-CD38 antibodies
|
|
BR122023024273A2
(pt)
|
2018-02-27 |
2024-02-20 |
Incyte Corporation |
Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
|
|
TWI823906B
(zh)
|
2018-03-09 |
2023-12-01 |
美商艾吉納斯公司 |
抗-cd73 抗體及其使用方法
|
|
BR112020016049A2
(pt)
|
2018-03-09 |
2020-12-08 |
Phanes Therapeutics, Inc. |
Anticorpos anti-cd73 e seus usos
|
|
EP3810610A1
(en)
|
2018-05-18 |
2021-04-28 |
Incyte Corporation |
Fused pyrimidine derivatives as a2a / a2b inhibitors
|
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
|
AU2019297361B2
(en)
|
2018-07-05 |
2024-06-27 |
Incyte Corporation |
Fused pyrazine derivatives as A2A / A2B inhibitors
|
|
CN112041348B
(zh)
|
2018-07-25 |
2023-09-22 |
天境生物科技(上海)有限公司 |
抗cd73抗pd-l1双特异性抗体
|
|
US12257340B2
(en)
|
2018-12-03 |
2025-03-25 |
Agensys, Inc. |
Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof
|
|
KR102063341B1
(ko)
*
|
2018-12-31 |
2020-01-07 |
다이노나(주) |
Icam-1에 특이적으로 결합하는 항체 및 그의 용도
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
US12221484B2
(en)
|
2019-03-29 |
2025-02-11 |
Lankenau Institute For Medical Research |
Anti-NMDA receptor antibodies and methods of use
|
|
JP7796008B2
(ja)
*
|
2019-09-13 |
2026-01-08 |
メモリアル スローン ケタリング キャンサー センター |
抗ｃｄ３７１抗体およびその使用
|
|
JP2022548881A
(ja)
|
2019-09-18 |
2022-11-22 |
ノバルティス アーゲー |
Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
|
|
JP7296467B2
(ja)
*
|
2019-12-18 |
2023-06-22 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｈｌａ－ａ２／ｍａｇｅ－ａ４に結合する抗体
|
|
KR20220137013A
(ko)
|
2020-01-03 |
2022-10-11 |
인사이트 코포레이션 |
Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법
|
|
CR20220317A
(es)
|
2020-01-03 |
2022-09-02 |
Incyte Corp |
Anticuerpos anti-cd73 y usos de estos
|
|
EP4088113A4
(en)
*
|
2020-01-12 |
2024-05-15 |
Vanderbilt University |
HUMAN ANTIBODIES AGAINST RIFT VALLEY FEVER VIRUS
|
|
CN111738980B
(zh)
*
|
2020-05-14 |
2023-08-04 |
北京深睿博联科技有限责任公司 |
一种医学影像的显示方法、计算机设备及存储介质
|
|
CN115867582A
(zh)
*
|
2020-05-29 |
2023-03-28 |
朝途生物疗法株式会社 |
抗cd73抗体及其用途
|
|
US20240101666A1
(en)
|
2020-10-23 |
2024-03-28 |
Bristol-Myers Squibb Company |
Lag-3 antagonist therapy for lung cancer
|
|
TW202241441A
(zh)
|
2020-12-29 |
2022-11-01 |
美商英塞特公司 |
包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
|
|
KR102887692B1
(ko)
*
|
2021-05-21 |
2025-11-18 |
주식회사 지놈앤컴퍼니 |
항-bcam 항체 또는 그의 항원 결합 단편
|
|
JP2024524880A
(ja)
*
|
2021-06-08 |
2024-07-09 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｄ８０および／またはｃｄ８６とｏｘ４０ｌに結合するタンパク質
|
|
WO2023034809A1
(en)
*
|
2021-08-30 |
2023-03-09 |
Lassen Therapeutics 1, Inc. |
Anti-il-11rα antibodies
|
|
CN114137231B
(zh)
*
|
2022-01-29 |
2022-04-29 |
北京大有天弘科技有限公司 |
一种血型不规则抗体的检测试剂盒及其应用
|
|
US12187806B2
(en)
|
2022-03-04 |
2025-01-07 |
Development Center For Biotechnology |
Anti-CD73 antibodies and use thereof
|
|
WO2024040195A1
(en)
|
2022-08-17 |
2024-02-22 |
Capstan Therapeutics, Inc. |
Conditioning for in vivo immune cell engineering
|
|
WO2024215624A2
(en)
*
|
2023-04-13 |
2024-10-17 |
A & G Pharmaceutical, Inc. |
Antibodies and conjugates against prostaglandin f2 receptor inhibitor and uses thereof
|
|
AU2024279278A1
(en)
|
2023-05-31 |
2025-12-18 |
Capstan Therapeutics, Inc. |
Lipid nanoparticle formulations and compositions
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
IL327045A
(en)
|
2023-10-05 |
2026-05-01 |
Capstan Therapeutics Inc |
Structure-restricted ionizable cationic lipids and lipid nanoparticles
|
|
US20250302763A1
(en)
|
2024-02-22 |
2025-10-02 |
Capstan Therapeutics, Inc. |
Immune engineering amplification
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|